COVID-19 and the Kidney: Should Nephrologists Care about COVID-19 rather than Maintaining Their Focus on Renal Patients?

4区 医学 Q3 Medicine Contributions to nephrology Pub Date : 2021-01-01 Epub Date: 2021-08-03 DOI:10.1159/000517752
Norberto Perico, Luca Perico, Claudio Ronco, Giuseppe Remuzzi
{"title":"COVID-19 and the Kidney: Should Nephrologists Care about COVID-19 rather than Maintaining Their Focus on Renal Patients?","authors":"Norberto Perico,&nbsp;Luca Perico,&nbsp;Claudio Ronco,&nbsp;Giuseppe Remuzzi","doi":"10.1159/000517752","DOIUrl":null,"url":null,"abstract":"<p><p>Clinical Background: The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapidly spread globally from late 2019, reaching pandemic proportions. Epidemiology: The related disease, COVID-19, exacerbates and progresses due to patients' abnormal inflammatory/immune responses, widespread endothelial damage, and complement-induced blood clotting with microangiopathy. COVID-19 manifests mainly as a respiratory illness. In cases of severe viral pneumonia, it may lead to acute respiratory distress syndrome, respiratory failure, and death. Challenges: Many extrapulmonary manifestations commonly occur, and a substantial proportion of patients with severe COVID-19 exhibit signs of kidney damage. Clinically, kidney involvement ranges from mild/moderate proteinuria and hematuria to acute kidney injury (AKI) requiring renal replacement therapy (RRT). The pathophysiologic mechanisms of kidney damage and AKI in patients with COVID-19 remain unclear but are known to be multifactorial. Current knowledge implies direct SARS-CoV-2-dependent effects on kidney cells (tubular epithelial cells and podocytes) and indirect mechanisms through the systemic effect of viral infection secondary to the critical pulmonary illness and its management. Prevention and Treatment: Standard-of-care strategies apply, as there is no specific evidence to suggest that COVID-19 AKI should be managed differently from other types in severely ill patients. If conservative management fails, RRT should be considered. The choice of RRT approaches and sequential extracorporeal therapies depends on local availability, resources, and expertise. The focus should now be on the long-term follow-up of COVID-19 patients, especially those who developed kidney injury and dysfunction. This represents an opportunity for integrated multidisciplinary research to clarify the natural history of COVID-19 renal sequelae and the best therapeutic interventions to mitigate them.</p>","PeriodicalId":10725,"journal":{"name":"Contributions to nephrology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8450831/pdf/cnp-0199-0229.pdf","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Contributions to nephrology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000517752","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/8/3 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 2

Abstract

Clinical Background: The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapidly spread globally from late 2019, reaching pandemic proportions. Epidemiology: The related disease, COVID-19, exacerbates and progresses due to patients' abnormal inflammatory/immune responses, widespread endothelial damage, and complement-induced blood clotting with microangiopathy. COVID-19 manifests mainly as a respiratory illness. In cases of severe viral pneumonia, it may lead to acute respiratory distress syndrome, respiratory failure, and death. Challenges: Many extrapulmonary manifestations commonly occur, and a substantial proportion of patients with severe COVID-19 exhibit signs of kidney damage. Clinically, kidney involvement ranges from mild/moderate proteinuria and hematuria to acute kidney injury (AKI) requiring renal replacement therapy (RRT). The pathophysiologic mechanisms of kidney damage and AKI in patients with COVID-19 remain unclear but are known to be multifactorial. Current knowledge implies direct SARS-CoV-2-dependent effects on kidney cells (tubular epithelial cells and podocytes) and indirect mechanisms through the systemic effect of viral infection secondary to the critical pulmonary illness and its management. Prevention and Treatment: Standard-of-care strategies apply, as there is no specific evidence to suggest that COVID-19 AKI should be managed differently from other types in severely ill patients. If conservative management fails, RRT should be considered. The choice of RRT approaches and sequential extracorporeal therapies depends on local availability, resources, and expertise. The focus should now be on the long-term follow-up of COVID-19 patients, especially those who developed kidney injury and dysfunction. This represents an opportunity for integrated multidisciplinary research to clarify the natural history of COVID-19 renal sequelae and the best therapeutic interventions to mitigate them.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
COVID-19和肾脏:肾病学家应该关心COVID-19而不是继续关注肾脏患者吗?
临床背景:新型严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)从2019年底开始在全球迅速传播,达到大流行的程度。流行病学:相关疾病COVID-19因患者异常的炎症/免疫反应、广泛的内皮损伤和补体诱导的血液凝固伴微血管病变而恶化和发展。COVID-19主要表现为呼吸道疾病。在严重的病毒性肺炎病例中,它可能导致急性呼吸窘迫综合征、呼吸衰竭和死亡。挑战:通常会出现许多肺外表现,并且相当大比例的严重COVID-19患者表现出肾脏损害的迹象。临床上,肾脏受累范围从轻度/中度蛋白尿和血尿到需要肾脏替代治疗(RRT)的急性肾损伤(AKI)。COVID-19患者肾损害和AKI的病理生理机制尚不清楚,但已知是多因素的。目前的知识表明,sars - cov -2对肾细胞(小管上皮细胞和足细胞)的直接依赖作用,以及通过继发于严重肺部疾病的病毒感染的全身效应及其管理的间接机制。预防和治疗:适用标准护理策略,因为没有具体证据表明,在重症患者中,COVID-19急性肾损伤的管理应与其他类型不同。如果保守治疗失败,应考虑RRT。RRT方法和顺序体外治疗的选择取决于当地的可用性、资源和专业知识。现在的重点应该放在COVID-19患者的长期随访上,特别是那些出现肾脏损伤和功能障碍的患者。这为综合多学科研究提供了机会,以阐明COVID-19肾脏后遗症的自然史,并找到缓解这些后遗症的最佳治疗干预措施。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Contributions to nephrology
Contributions to nephrology 医学-泌尿学与肾脏学
CiteScore
1.50
自引率
0.00%
发文量
0
审稿时长
6-12 weeks
期刊介绍: The speed of developments in nephrology has been fueled by the promise that new findings may improve the care of patients suffering from renal disease. Participating in these rapid advances, this series has released an exceptional number of volumes that explore problems of immediate importance for clinical nephrology. Focus ranges from discussion of innovative treatment strategies to critical evaluations of investigative methodology. The value of regularly consolidating the newest findings and theories is enhanced through the inclusion of extensive bibliographies which make each volume a reference work deserving careful study.
期刊最新文献
Oxiris Membrane in Sepsis and Multiple Organ Failure. The Process of Adsorption and Cartridge Design. Introduction. Hemoperfusion in Trauma. Monitoring Treatment, Risks and Side Effects.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1